Table 1.

Issues Concerning the Cost-Effectiveness of PCSK9 Inhibitors

1) Overall perspective

2) Selection of appropriate patients

3) Choice of comparator group

4) Incremental effect of PCSK9 on life expectancy compared to the control

5) Incremental effect of PCSK9 on non-fatal events

6) Effect of non-fatal events on health status

7) Incremental cost of PCSK9

8) Cost savings by preventing events

9) Cost savings by preservation of productivity

10) Incremental direct costs due to prolongation of life